Integrating Buprenorphine Naloxone Into An Opioid Treatment Program



February 12, 2013

Integrating Buprenorphine/Naloxone Into An Opioid Treatment Program

Laura F. McNicholas, M.D., Ph.D.
Director, Buprenorphine Program
Philadelphia VA Medical Center
Clinical Associate Professor
University of Pennsylvania
Philadelphia, PA

This webinar will address integrating buprenorphine/naloxone or buprenorphine into an Opioid Treatment Program (OTP) that is providing methadone maintenance. Patient selection, dosing, staff, and financing issues must be considered.   Dispensing, especially in light of the discontinuation of buprenorphine/ naloxone tablets, will be addressed.
 
The impact of the new Federal rule "Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction:  Proposed Modification of Dispensing Restrictions for Buprenorphine and Buprenorphine Combinations as Used in Approved Opioid Treatment Programs" will be discussed.  These regulations significantly liberalize the take-home policies for OTP's when using buprenorphine products in the clinic.  Potential positive and negative implications will be addressed.

Presentation slides 

Federal Rule